Understand the source comparison
How Peptides Are Made: Synthesis Method Comparison
Different synthesis strategies produce peptides with varying purity, scalability, and cost profiles. The choice of method depends on peptide length, target purity, and production scale. Solid-Phase Synthesis (SPPS) 95–99% 2–50 amino acids, mg to g scale Resear
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Different synthesis strategies produce peptides with varying purity, scalability, and cost profiles. The choice of method depends on peptide length, target purity, and production scale.
- Solid-Phase Synthesis (SPPS)
- 95–99%
- 2–50 amino acids, mg to g scale
- Research-grade peptides requiring high purity and custom sequences
- Difficult for sequences >50 residues due to cumulative coupling errors
- Gold standard for research peptides. Automation enables reproducibility and sequence verification at every step
- Liquid-Phase Synthesis
- 85–95%
- Economical for large-scale production (kg scale)
- Industrial peptides where cost matters more than purity
- Lower purity, more complex purification, limited to simpler sequences
- Suitable for bulk production but lacks the precision required for biological assays
- Recombinant Expression
- Variable (often requires refolding)
- Unlimited scale once expression system is optimised
- Large therapeutic peptides and proteins (insulin, growth factors)
- Requires molecular biology infrastructure, post-translational modifications may differ from native peptide
- Only viable method for very long peptides or those requiring specific folding. Not cost-effective for short research peptides
- Chemical Ligation (NCL)
- 90–98%
- Used to combine shorter SPPS fragments into longer sequences
- Peptides 50–200 residues where SPPS alone fails
- Requires cysteine residues at ligation sites, complex optimisation
- Niche application for difficult sequences. Most research peptides don't require this approach
- SPPS dominates research peptide production because it offers the best combination of purity, sequence fidelity, and scalability for peptides in the 5–40 residue range. Which encompasses the vast majority of bioactive research compounds. Liquid-phase synthesis is cheaper per gram but introduces purification challenges that offset the cost savings unless production scale exceeds several kilograms. Recombinant expression makes sense for peptides like Thymalin or Cerebrolysin, where the peptide is part of a larger protein complex, but for shorter sequences like BPC-157 or Ipamorelin, SPPS is faster, cleaner, and more reliable.